Orlistat impurity as well as synthesis method and application thereof

Through the synthesis route under specific conditions, the low synthesis efficiency and purity of orlistat impurities A-E is solved, providing efficient reference products, and improving the accuracy and efficiency of drug quality control.

CN119039251AInactive Publication Date: 2024-11-29ARGUS PHARMA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411109125.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The synthesis method of orlistat impurities A to E in the prior art lacks high efficiency, simplicity and low product purity, resulting in poor accuracy of qualitative and quantitative measurements, and lack of supply of reference products at home and abroad, affecting drug quality control.

Method used

The synthesis route under specific conditions, including photodelay reaction, hydrogenation, reaction under alkali and solvent conditions, and the action of pH buffering reagents, etc., prepare compounds A to E, select appropriate catalysts and solvents to control reaction conditions, and improve product purity. and synthesis efficiency.

Benefits of technology

The rapid, simple and efficient synthesis of compounds A-E was achieved, with the product purity reaching 97.37%-98.0%, which improved the quality control accuracy of orlistat raw materials and preparations, and provided a reference product to reduce the risk of clinical drug use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039251A_ABST
    Figure CN119039251A_ABST
Patent Text Reader

Abstract

The invention discloses an orlistat impurity as well as a synthesis method and application thereof, and belongs to the technical field of medicine synthesis. The compounds A-E are directionally synthesized under specific conditions, and the compounds A-E are orlistat impurities and can be used as reference substances for content determination and impurity detection of orlistat, so that the quality of raw material medicines and preparations of orlistat can be controlled and improved. The synthesis method provided by the invention can be used for rapidly, accurately and efficiently synthesizing the compounds A-E, and the product purity is relatively high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and particularly relates to an orlistat impurity and a synthesis method and application thereof. Background Art

[0002] Orlistat, chemical name: (S)-2-carboxamido-4-methyl-pentanoic acid-(S)-l-[[(2S,3S)-3-hexyl-4-oxo-oxetanyl]methyl]-dodecyl ester, chemical structure is as follows:

[0003]

[0004] Orlistat was originally developed by CHEPHAPHARM Arzneimittel GmbH and was first approved by EMA on July 29, 1998 for sale in the EU as a prescription drug under the trade name "XENICAL" with a specification of 120 mg. It was approved by FDA for sale in the United States on April 23, 1999 and by NMPA for sale in China on October 31, 2000. It is mainly used clinically for the long-term treatment of obesity and overweight, including patients with obesity-related risk factors.

[0005] Orlistat is a reversible gastrointestinal lipase inhibitor that inactivates the enzymes by forming covalent bonds with the active serine residue sites of gastric lipase and pancreatic lipase in the stomach and small intestine. The inactivated enzymes cannot hydrolyze fat (triglycerides) in food into absorbable free fatty acids and monoglycerides. Undigested triglycerides cannot be absorbed, thereby reducing calorie intake and achieving the effect of controlling weight. Orlistat is non-selective for gastrointestinal lipase and can inhibit a variety of physiological triglyceride lipases and diglyceride lipases, including gastric lipase, pancreatic lipase, carboxyl ester lipase, lipoproteinase, hepatic lipase, and hormone-sensitive lipase.

[0006] Orlistat is the only drug currently approved in my country for treating obese or overweight patients, and it mainly reduces body weight by reducing fat absorption in food. Currently, there are two preparation methods for orlistat: biological fermentation method and chemical synthesis method. The orlistat impurities of the present invention are impurities related to the synthesis of the chemical synthesis method.

[0007] Compounds A to E are impurities in the synthesis process of orlistat or impurities in the degradation of orlistat. Their chemical structures and names are as follows:

[0008]

[0009] The name of compound A is: (S)-1-((2S,3S)-3-hexyl-4-oxoalkane-2-yl)tridecane-2-yl L-leucine ester; the name of compound B is: (3S,4S,6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-ylformyl-L-leucine salt; the name of compound C is: (3S,4R,6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H- Pyran-4-hydroxy-N-formyl-L-leucine ester; the name of compound D is: (S)-1-((2S,3S)-3-hexyl-4-oxoalkane-2-yl)tridecane-2-yl (2S)-2-formamide-3-methylpentanoate; the name of compound E is: (7S,8S,10S)-8-hydroxy-7-(((S)-1-phenylethyl)carbamoyl)n-heneicosane-10-ylformamide-L-leucine ester.

[0010] Compounds A to E are orlistat impurities and can be used as reference substances to improve the quality of orlistat raw materials and preparations and reduce the risk of clinical use. However, there is currently no supply of reference substances for impurities A to E at home and abroad, and there is no report on the synthesis method of impurities A to E in domestic and foreign literature and patents. The impurity determination can only be carried out by the main component self-reference method, which makes the qualitative and quantitative accuracy of impurities A to E poor, the product preparation is time-consuming and inconvenient, the efficiency is low, the reaction conditions are not mild and controllable, and the product purity is low. Summary of the invention

[0011] The main purpose of the present invention is to provide an orlistat impurity and a synthesis method and use thereof, so as to achieve rapid, simple and efficient synthesis of orlistat impurities A to E, while the reaction conditions are controllable, the accuracy is better, and the product purity is high.

[0012] In order to achieve the above object, the present invention provides a compound as shown in any one of formulas A to E:

[0013]

[0014]

[0015] In one aspect of the present invention, a method for synthesizing the aforementioned compound is provided. The synthetic route of formula A comprises the following steps: subjecting compound I to a Mitsunobu reaction with N-Cbz-L-leu in the presence of catalyst 1 and solvent 1 to obtain compound II; and then subjecting compound II to hydrogenation to obtain compound A;

[0016]

[0017] Furthermore, the solvent 1 is selected from one or more of tetrahydrofuran, toluene or dioxane; the catalyst 1 is selected from triphenylphosphine and / or diisopropyl azodicarboxylate; the reaction temperature for preparing the compound II is 0 to 10°C, more preferably 8 to 10°C, and the reaction time is 1.5 to 2.5h.

[0018] Furthermore, the synthesis route of formula B comprises the following steps: firstly reacting compound IV (orlistat) under the conditions of base and solvent, and then reacting the intermediate product obtained by the reaction with compound III (N-formyl-L-leucine) under the conditions of organic base to obtain said formula B;

[0019]

[0020] Furthermore, the base is selected from one or more of KOH, NaOH or Na3PO4, more preferably KOH; the organic base is selected from one or more of dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine, more preferably dimethylaminopyridine; in preparing the intermediate product, the solvent is selected from tetrahydrofuran and / or dioxane, more preferably dioxane.

[0021] Furthermore, the reaction temperature of compound IV (orlistat) under the conditions of base and solvent is 20-30°C, and the reaction time is 2-3 hours; the reaction temperature of the intermediate product and compound III (N-formyl-L-leucine) under the conditions of organic base is room temperature, and the reaction time is 16-18 hours.

[0022] Furthermore, the synthesis route of Formula C comprises the following steps: reacting Compound IV (orlistat) under the action of a pH buffer reagent to prepare Formula C;

[0023]

[0024] Furthermore, the pH buffer reagent is selected from one or more of sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate or dipotassium hydrogen phosphate, more preferably sodium dihydrogen phosphate; the pH value of the pH buffer reagent is 5.0-7.5, more preferably 6.8.

[0025] Further, compound IV (orlistat) reacts with a pH buffer reagent under reflux conditions, the reaction temperature is 100-110° C., and the reaction time is 100-120 h.

[0026] Furthermore, the synthesis route of Formula D comprises the following steps: reacting Compound I with Compound V in the presence of Catalyst 2 and Solvent 2 to obtain Formula D;

[0027]

[0028] Furthermore, the reaction temperature of compound I and compound V is 0-10°C, and the reaction time is 3-8h.

[0029] Furthermore, the synthesis route of Formula E comprises the following steps: reacting Compound III (N-formyl-L-leucine) with Compound VI in the presence of a solvent 2 and a catalyst 2 to obtain Formula E;

[0030]

[0031] Furthermore, the solvent 2 is selected from one or more of tetrahydrofuran, dioxane, toluene or acetonitrile; and the catalyst 2 is selected from triphenylphosphine and / or diisopropyl azodicarboxylate.

[0032] Furthermore, the reaction temperature of compound III and compound VI is 0-10° C., and the reaction time is 3-8 h.

[0033] Another aspect of the present invention provides a use of the aforementioned compounds A to E as reference substances in the quality analysis of orlistat raw materials and preparations.

[0034] Compared with the prior art, the present invention has the following beneficial effects: the present invention adopts specific conditions to synthesize compounds A to E in a directional manner, and compounds A to E are orlistat impurities, which can be used as reference substances for orlistat content determination and impurity detection, which can control and improve the quality of orlistat raw materials and preparations. The synthesis method of the present invention can synthesize compounds A to E quickly, accurately and efficiently, and the product purity is high, the purity of compound A is 97.37%, the purity of compound B is 97.51%, the purity of compound C is 96.23%, the purity of compound D is 95.81%, and the purity of compound E is 98.0%. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The synthetic route diagram of compounds A to E in the specific embodiments of the present invention is shown;

[0036] Figure 2 The specificity profiles of orlistat impurity A and impurity D are shown;

[0037] Figure 3 The detection spectrum of impurity A and impurity D in the orlistat test sample is shown;

[0038] Figure 4 The specificity profiles of orlistat impurities B, C, and E are shown;

[0039] Figure 5 The detection spectrum of impurities B, C, and E in the orlistat test sample is shown. DETAILED DESCRIPTION

[0040] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments in the invention, all other embodiments obtained by ordinary technicians in the field without creative labor are within the scope of protection of the present invention. Unless otherwise specified, the reagents used in the embodiments can be easily obtained from commercial companies or homemade. The test sample is homemade by the company, with batch number FP202310-025.

[0041] Example 1

[0042] The synthesis method of orlistat impurity A and the synthesis of orlistat impurity (S)-1-((2S, 3S)-3-hexyl-4-oxoalkane-2-yl)tridecane-2-yl L-leucine ester (compound A) comprise the following steps:

[0043] Dissolve compound I (3.00 g, 6.05 mmol) in tetrahydrofuran (12 mL), add triphenylphosphine (2.88 g, 7.87 mmol) and N-benzyloxycarbonyl-L-leucine (N-Cbz-L-leu, 2.38 g, 6.41 mmol), slowly drop diisopropyl azodicarboxylate (2.74 g, 9.68 mmol) when the temperature drops to 0-10°C, raise the temperature to 8-10°C after the addition is complete, and react for 1.5-2.5 h;

[0044] The reaction process was monitored by a thin layer chromatography plate. After the reaction was completed, tetrahydrofuran was removed by concentrating under reduced pressure at 40-45°C until no fraction flowed out. When the concentrate was cooled to 20-30°C, n-heptane (18 mL) was added, and then washed with methanol aqueous solution (methanol volume ratio 70%, 12 mL), and finally washed with purified water (3 mL). The organic phase was cooled to -5-0°C for crystallization, and the precipitated solid was filtered, and the filter cake was collected and vacuum dried at 20-30°C to constant weight to obtain compound II;

[0045] Compound II was dissolved in tetrahydrofuran (150 mL), and Pd-C catalyst (loading amount 5%, 3 g) was added, and hydrogenation reaction was carried out at room temperature and normal pressure for 3 to 4 hours. After the reaction was completed, the catalyst was filtered out and the filtrate was concentrated under reduced pressure at 40°C to obtain a colorless oil. 2.17 g of impurity compound A was obtained, with a yield of 68.4% and a purity of 97.37%.

[0046] The analysis data of the NMR spectrum and mass spectrum of its impurity compound A are as follows: 1H-NMR (DMSO-d6, 600MHz) δ: 0.80-0.82ppm (m, 6H), 0.88-0.90ppm (m, 6H), 1.15-1.23ppm (m, 26H), 1.41-1.51ppm (m, 3H), 1.53-1.66ppm (m, 7H), 3.54ppm (m, 2H), 4.07-4.08ppm (d, J=6.0Hz, 1H), 4.21-4.22ppm (m, 1H), 5.05ppm (m, 1H); 13 C-NMR (DMSO-d6, 600MHz) δ: 13.55ppm, 13.91ppm, 22.07ppm, 22.77ppm, 24.06ppm, 27.01ppm, 28.62ppm, 28.71ppm, 28.99ppm, 29.02ppm, 29.07pp m, 30.39ppm, 30.97ppm, 31.29ppm, 32.92ppm, 34.36ppm, 49.43ppm, 50.78ppm, 69.87ppm, 72.47ppm; 171.16ppm, 174.21ppm; MS(m / z): 468.4[M+H] + .

[0047] Example 2

[0048] The synthesis method of orlistat impurity B, the synthesis of (3S, 4S, 6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-ylformyl-L-leucine salt (compound B), comprises the following steps:

[0049] Compound I (3.00 g, 6.05 mmol) was dissolved in tetrahydrofuran (12 mL), and triphenylphosphine (2.88 g, 7.87 mmol) and compound III (1.01 g, 6.41 mmol) were added. When the temperature was lowered to 0-10°C, diisopropyl azodicarboxylate (2.74 g, 9.68 mmol) was slowly added dropwise. After the addition was completed, the temperature was raised to 8-10°C and the reaction was carried out for 1.5-2.5 h. The reaction was monitored by thin layer chromatography. After the reaction is completed, tetrahydrofuran is removed by concentrating under reduced pressure at 40-45°C until no fraction flows out, the concentrate is cooled to 20-30°C, n-heptane (18 mL) is added, and the mixture is washed with a methanol aqueous solution (methanol volume ratio 70%, 12 mL), and finally washed with purified water (3 mL), the organic phase is cooled to -5-0°C for crystallization, the precipitated solid is filtered, the filter cake is collected and vacuum dried at 20-30°C to constant weight to obtain compound IV (oselita).

[0050] Weigh compound IV (oselita, 5.00 g, 8.1 mmol), add potassium hydroxide (1 mol / L, 16 mL) and dioxane (0.43 L) to react, control the reaction temperature at 24 ° C, and react for 2.5 hours; add hydrochloric acid (1 mol / L, 17.6 ml) for post-treatment to acidify, concentrate under reduced pressure at 60 ° C, and recrystallize from n-heptane / ethyl acetate (V / V=1:1) to obtain a white solid (2.83 g);

[0051] A white solid (2.83 g) and compound III (N-formyl-L-leucine, 1.27 g, 7.9 mmol) were added to dimethylacetamide (12 ml), 4-dimethylaminopyridine (0.16 g, 1.31 mmol) was added under stirring, the temperature was lowered to 5°C, dicyclohexylcarbodiimide (1.82 g, 8.8 mmol) was added, and the temperature was raised to room temperature for reaction for 18 h; the reaction progress was monitored by thin layer chromatography. After the reaction was completed, water (100 mL) was added, and the mixture was extracted with methyl tert-butyl ether (100 mL). After concentration, the mixture was purified by silica gel column chromatography with an eluent of n-heptane / ethyl acetate (V / V: 10:1) to obtain 1.32 g of a white solid, which was impurity compound B, with a yield of 26.3% and a purity of 97.51%.

[0052] The nuclear magnetic spectrum and mass spectrum analysis data of the impurity compound B are as follows: 1H-NMR (DMSO-d6, 600MHz) δ: 0.84-0.90ppm (m, 12H), 1.24ppm (m, 27H), 1.50-1.53ppm (m, 5H), 1.57-1.58ppm (m, 3H), 2.70ppm (m, 1H), 4.25-4.47ppm (m, 2H), 5.15-5.22ppm (m, 1H), 8.03-8.04ppm (m, 1H), 8.53-8.54ppm (d, J = 6.0Hz, 1H); 13C-NMR (DMSO-d6, 600MHz) δ: 1 3.87ppm, 21.38ppm, 21.50ppm, 22.36ppm, 22.09ppm, 26.10ppm, 26.23ppm, 28.63ppm, 28.72ppm, 28.96ppm, 28.99ppm, 29.03ppm, 31.12ppm, 31.30p pm, 31.86ppm, 35.18ppm, 39.08ppm, 25.84ppm, 49.60ppm, 49.66ppm, 68.16ppm, 75.26ppm, 161.03pm, 171.07ppm, 171.55ppm; MS (m / z): 518.4[M+Na] + .

[0053] Example 3

[0054] The synthesis method of orlistat impurity C, the synthesis of (3S, 4R, 6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-hydroxy-N-formyl-L-leucine ester (compound C), comprises the following steps:

[0055] Weigh compound I (5g, 40mmol) into a reaction bottle, add 1,4-dioxane (400ml) and sodium dihydrogen phosphate dihydrate buffer solution (reaction solution pH = 6.8, adjust pH with sodium hydroxide), heat and reflux for 120h. After the reaction is completed, concentrate to remove the solvent, add water (500m) and dichloromethane (500mL) for extraction; the organic phase is washed with water (500mL), saturated sodium bicarbonate aqueous solution (500mL), and saturated sodium chloride aqueous solution (500mL) in sequence, and concentrated to obtain a yellow oil. After three column chromatography purifications, 3.18g of yellow oil was obtained, which is impurity compound C, with a yield of 64.0% and a purity of 95.6%.

[0056] The nuclear magnetic spectrum and mass spectrum analysis data of the impurity compound C are as follows: 1H-NMR (DMSO-d6, 600MHz) δ: 0.83-0.91ppm (m, 12H), 1.22-1.37ppm (m, 27H), 1.49-1.67ppm (m, 9H), 2.14-2.18ppm (m, 1H), 2.58-2.60ppm (m, 1H), 4.27-4.38ppm (m, 2H), 5.05-5.06ppm (m, 1H), 8.05ppm (s, 1H), 8.49-8.51ppm (m, 1H); 13C-NMR (DMSO-d6, 600MHz) δ: 13.92ppm, 21. 22ppm, 21.30ppm, 21.96ppm, 22.07ppm, 22.55ppm, 22.62ppm, 24.21ppm, 25.81ppm, 27.50ppm, 28.62ppm, 28.68ppm, 28.88ppm, 28.93ppm, 28.98ppm, 28. 99ppm, 30.94ppm, 31.27ppm, 33.64ppm, 34.87ppm, 46.05ppm, 49.20ppm, 69.67ppm, 75.21ppm, 161.05ppm, 171.28ppm, 171.41ppm; MS(m / z): 496.4[M+H] + .

[0057] Example 4

[0058] The synthesis method of orlistat impurity D, the synthesis of (S)-1-((2S,3S)-3-hexyl-4-oxoalkane-2-yl)tridecane-2-yl (2S)-2-formamide-3-methylpentanoate (compound D), comprises the following steps:

[0059] Weigh compound I (2.13 g, 6.0 mmol) and dissolve it in tetrahydrofuran (8.5 mL), then add triphenylphosphine (2.05 g, 7.81 mmol) and compound V (1.01 g, 6.37 mmol), slowly cool to below 10°C, dropwise add diisopropyl azodicarboxylate (1.94 g, 9.59 mmol), and after the addition is complete, heat to 8-10°C for reaction;

[0060] After the reaction is completed, the mixture is concentrated under reduced pressure at 45°C until there is no liquid, and then n-heptane (100 mL) is added. The mixture is washed with methanol-water solution (methanol volume ratio 70%, 100 mL), and washed once with purified water (100 mL). The organic phase is cooled to 0°C, crystallized and filtered to obtain a crude product: the crude product is purified by recrystallization from heptane to obtain 2.53 g of a white solid, which is impurity compound D, with a yield of 85.0% and a purity of 95.81%.

[0061] The nuclear magnetic spectrum and mass spectrum analysis data of the impurity compound D are as follows: 1H-NMR (DMSO-d6, 600MHz) δ: 0.83-0.87ppm (m, 12H), 1.23-1.30ppm (m, 26H), 1.35-1.39ppm (m, 2H), 1.54-1.57ppm (m, 4H), 1.63-1.67ppm (m, 1H), 2.02-2.03ppm (m, 1H), 2.10-2.13ppm (m, 1H), 3.32-3.50ppm (m, 1H), 4.25-4.27ppm (m, 1H), 4.35-4.36ppm (m, 1H), 4.89ppm (m, 1H), 8.06-8.07ppm (s, 1H), 8.44-8.45ppm (m, 1H) ; 13C-NMR (DMSO-d6, 600MHz) δ: 11.07ppm, 13.87ppm, 13.92ppm, 15.42ppm, 24.31ppm, 2 4.39ppm, 25.95ppm, 26.79ppm, 28.33ppm, 28.62ppm, 28.67ppm, 28.81ppm, 28.84ppm, 28 .97ppm, 28.98ppm, 30.95ppm, 31.27ppm, 33.19ppm, 35.99ppm, 37.62ppm, 55.28ppm, 55. 53ppm, 71.43ppm, 74.31ppm, 161.12ppm, 170.54ppm, 171.31ppm; MS(m / z):518.4[M+Na] + .

[0062] Example 5

[0063] The synthesis method of orlistat impurity E, the synthesis of (7S,8S,10S)-8-hydroxy-7-(((S)-1-phenylethyl)carbamoyl)n-heneicosane-10-ylcarboxamido-L-leucine ester (compound E), comprises the following steps:

[0064] Weigh compound VI (3.0 g, 6.3 mmol) into a reaction flask, add tetrahydrofuran (30 mL) and stir to dissolve, then add triphenylphosphine (2.15 g, 8.2 mmol) and compound III (N-formyl-L-leucine, 1.065 g, 6.7 mmol), cool to -10 to 0°C, slowly dropwise add diisopropyl azodicarboxylate (2.04 g, 10.1 mmol), raise the temperature to 8 to 10°C after the addition is complete, and stir to react; monitor the reaction progress by thin layer chromatography, concentrate under reduced pressure after the reaction is complete, and purify by silica gel column chromatography, the elution solvent is n-heptane / ethyl acetate (V / V=20:1) to obtain 1.8 g of colorless oil, which is impurity compound E, with a yield of 46.0% and a purity of 98.0%.

[0065] The nuclear magnetic spectrum and mass spectrum analysis data of the impurity compound E are as follows: 1H-NMR (DMSO-d6, 600MHz) δ: 0.83-0.89ppm (m, 12H), 1.33-1.39ppm (m, 4H), 1.16-1.29ppm (m, 24H), 1.46-1.52ppm (m, 8H), 2.26-2.28ppm (m, 1H), 3.52-3 .53ppm (m, 1H), 4.27-4.30ppm (m, 1H), 4.95-4.97ppm (m, 2H), 4.75ppm (brs, 1H), 7.20-7.2 1ppm (m, 1H), 7.27-7.33ppm (m, 4H), 8.03ppm (s, 1H), 8.31-8.32ppm (m, 1H), 8.41-8.43ppm (m, 1H); 13C-NMR (DMSO-d6, 600MHz) δ: 13.93ppm, 22.62ppm, 24.18ppm, 24.21ppm, 26.93pp m, 28.50ppm, 28.72ppm, 28.83ppm, 28.89ppm, 28.92ppm, 29.02ppm, 29.04ppm, 31.24ppm, 3 1.31ppm, 32.79ppm, 47.39ppm, 49.15ppm, 50.65ppm, 68.26ppm, 72.32ppm, 125.97ppm, 126 .47ppm, 128.05ppm, 144.52ppm, 160.90ppm, 171.52ppm, 173.05ppm; MS(m / z):617.5[M+H] + .

[0066] The synthetic routes of orlistat impurity compounds A to E provided in the embodiments of the present invention are as follows: Figure 1 The detection method of the orlistat impurity compounds A to E of the present invention is as follows:

[0067] Compounds A and D were controlled using one set of detection methods, and compounds B, C, and E were controlled using another set of detection methods.

[0068] The detection method of orlistat impurity compounds A and D (HPLC normalization method) is as follows: chromatographic column: Titank C18 (150 mm×4.6 mm, 3 μm); mobile phase: 0.05% phosphoric acid aqueous solution as mobile phase A, acetonitrile as mobile phase B, detection wavelength 195 nm; column temperature: 30°C; flow rate: 1.0 mL / min; injection volume: 20 μL, gradient elution mode, the elution gradient is as shown in Table 1 below.

[0069] Table 1

[0070]

[0071] Under the above chromatographic conditions, a specificity test was conducted on orlistat impurity compounds A and D. The detection limits were as follows: the content of impurity A was ≤0.1%, the content of impurity D was ≤0.1%, the content of other individual impurities was ≤0.1%, and the content of total impurities was ≤1.0%. Figure 2 As shown in the figure, it can be seen that impurity A and impurity D can be effectively detected, and the separation between each impurity is good. The detection conditions have good specificity for impurity A and impurity D. The company's homemade orlistat is used as a test product, with batch number FP202310-025. The above chromatographic conditions are used to detect impurity A and impurity D. The detection spectrum is as follows Figure 3 As shown, it can be seen that orlistat contains impurity A and impurity D. After calculation, the content of impurity A is 0.05%, and the content of impurity D is 0.09%.

[0072] The detection method of orlistat impurity compounds B, C, and E (HPLC normalization method) is as follows: chromatographic column: Waters Nova-Pak C18 (150 mm×3.9 mm, 4 μm); detection wavelength: 195 nm; column temperature: 20°C; flow rate: 1 mL / min; solvent: methanol; injection volume: 20 μL; mobile phase: acetonitrile-pure water (M / M=80:20) solution as mobile phase. Limit: calculated by external standard method, impurity B≤0.1%, impurity C≤0.1%, impurity E≤0.1%.

[0073] Under the above chromatographic conditions, specificity experiments were conducted on orlistat impurity compounds B, C, and E. The specificity spectra are shown in the following figure. Figure 4As shown in the figure, it can be seen that impurities B, C, and E can be effectively detected, and the separation between each impurity is good. The detection conditions have good specificity for impurities B, C, and E. The company's homemade orlistat is used as a test product, with batch number FP202310-025. The above chromatographic conditions are used to detect impurities B, C, and E. The detection spectrum is shown as follows Figure 5 As shown, it can be seen that orlistat contains impurities B, C, and E. After calculation, impurity B is 0.09%, impurity C is 0.01%, and impurity E is 0.02%.

[0074] The above-described embodiments only represent the embodiments of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. The present invention can also be implemented in other specific ways or other specific forms without departing from the gist or essential features of the present invention. Therefore, the described embodiments should be regarded as illustrative rather than restrictive in any respect. The scope of the present invention should be described by the attached claims, and any changes equivalent to the intention and scope of the claims should also be included in the scope of the present invention.

Claims

1. A compound as shown in any one of formulas A to E:

2. The method for synthesizing the compound according to claim 1, characterized in that: The synthesis route of formula A comprises the following steps: subjecting compound I to a Mitsunobu reaction with N-Cbz-L-leu in the presence of catalyst 1 and solvent 1 to obtain compound II; and then subjecting compound II to hydrogenation to obtain formula A; 3. The method for synthesizing the compound according to claim 2, characterized in that: The synthesis route of formula B comprises the following steps: firstly reacting compound IV under the condition of base and solvent, and then reacting the intermediate product obtained by the reaction with compound III under the condition of organic base to obtain said formula B, wherein said compound III is N-formyl-L-leucine; 4. The method for synthesizing the compound according to claim 3, characterized in that: The solvent 1 is selected from one or more of tetrahydrofuran, toluene or dioxane; Preferably, the catalyst 1 is selected from triphenylphosphine and / or diisopropyl azodicarboxylate; Preferably, the reaction temperature for preparing the compound II is 0 to 10°C; Preferably, the base is selected from one or more of KOH, NaOH or Na3PO4; Preferably, in preparing the intermediate product, the solvent is selected from tetrahydrofuran and / or dioxane; Preferably, the organic base is selected from one or more of dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine.

5. The method for synthesizing the compound according to claim 2, characterized in that: The synthetic route of formula C comprises the following steps: reacting compound IV under the action of a pH buffer reagent to prepare the formula C; wherein the compound IV is orlistat; 6. The method for synthesizing the compound according to claim 5, characterized in that: The pH buffer reagent is selected from one or more of sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate or dipotassium hydrogen phosphate; preferably, the pH value of the pH buffer reagent is 5.0-7.

5.

7. The method for synthesizing the compound according to claim 2, characterized in that: The synthetic route of formula D comprises the following steps: reacting compound I with compound V in the presence of catalyst 2 and solvent 2 to obtain said formula D; 8. The method for synthesizing the compound according to claim 2, characterized in that: The synthetic route of Formula E comprises the following steps: reacting Compound III with Compound VI in the presence of a solvent 2 and a catalyst 2 to obtain Formula E; 9. The method for synthesizing the compound according to claim 7 or 8, characterized in that: The solvent 2 is selected from one or more of tetrahydrofuran, dioxane, toluene or acetonitrile; the catalyst 2 is selected from triphenylphosphine and / or diisopropyl azodicarboxylate.

10. The use of the compound according to claim 1, characterized in that The compounds A to E are used as reference substances for content determination and impurity detection of orlistat raw materials or preparations.

Citation Information

Patent Citations

  • 2-hexyl-3-hydroxy-5-R1-oxy hexadecyl carboxylic R2 ester and its prepn and use in preparing orlistat as slimming medicine

    CN101066924A

  • Processes for the production of (-)-tetrahydrolipstatin and intermediates thereof

    WO2004065346A1